Form 4: Coherus Oncology CFO Executes Option Repricing

Coherus Oncology CFO Bryan J. McMichael completed an option repricing program approved by stockholders on May 29, 2026.

Summary

• CFO Bryan J. McMichael participated in a company-wide option repricing program.
• A total of 220,000 underwater stock options with exercise prices ranging from $5.44 to $14.76 were cancelled.
• These were replaced with 220,000 new stock options at an exercise price of $1.59 per share.
• The new options carry an expiration date of May 29, 2036.
• The repricing is contingent upon the reporting person remaining in service to the issuer through May 29, 2027.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-negative signal, as it highlights that the company's equity compensation has significantly underperformed, necessitating a reset to retain management.

Positives

• Aligns executive incentives with current share price performance.
• Retention mechanism for key leadership through the May 2027 service requirement.

Negatives

• Repricing indicates that previous equity-based compensation failed to provide intended value due to significant share price decline.
• Dilutive potential or accounting expense impact associated with the repricing program.

Risks

• Continued share price volatility could render the new $1.59 strike price underwater again.
• Potential shareholder dissatisfaction regarding the repricing of executive equity.

Future Outlook

The repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027, suggesting a focus on executive retention.

Management Comments

• The repricing applies to stock options held by current employees and other service providers previously priced at or over $5.

Industry Context

StockSavvy.ai notes that option repricing is a common, albeit controversial, practice in the biotechnology sector when share prices experience significant drawdowns, often used as a tool to prevent talent attrition when existing equity grants lose their incentive value.

Comparison to Industry Standards

• Repricing programs are generally viewed as a last-resort retention tool in the biotech industry.
• The requirement for continued service for one year post-repricing is consistent with standard corporate governance practices for such programs.

Corporate Governance

Stakeholder Impact

• Shareholders may experience dilution or accounting charges related to the repricing.
• Employees and executives benefit from the reset of incentive strike prices.

Next Steps

• Reporting person must remain in service through May 29, 2027, to finalize the repricing benefit.

Key Dates

Recommendation

The filing reflects internal compensation adjustments rather than operational or financial performance shifts. Investors should monitor the company's core oncology pipeline progress rather than executive equity movements.

Keywords

Coherus Oncology, CHRS, Option Repricing, Executive Compensation, SEC Form 4, CFO